FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill

(By Ed Silverman for STAT)

Pfizer won a crucial battle in its quest to widen the market for its Chantix smoking cessation pill late Wednesday when a federal advisory panel recommended that a serious warning about neuropsychiatric side effects should be removed from the product labeling. Continue reading article here……

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.